EP426 Predictive value of the sentinel lymph node biopsy (SLNB) in early-stage cervical cancer: is pelvic lymphadenectomy replaceable?

Introduction/Background We analyzed the predictive value of the Sentinel Lymph Node Biopsy (SLNB) in order to assess its safety and reliability. Methodology Retrospective analyses of patients diagnosed with early-stage cervical cancer (ESCC) between June 2010 and June 2017. All patients underwent SLNB followed by pelvic lymphadenectomy (PL). Stage was IA1 to IIA1. Results 61(39,8%) met the inclusion criteria. The mean tumor size was 21.1 mm preoperatively. A 70% of the patients had a tumor size ≤2 cm. We performed 47 (77.0%) SLNB followed by bilateral PL. According to the technique we obtained bilateral detection in 30/47 patients (63,8%). Unilateral detection was observed in 12/47 cases (25,5%) and bilateral failure in 5/47 cases (10.6%). The lymph node status was positive in 4/47 cases (8.5%) in which para-aortic lymphadenectomy was accomplished for staging. The overall detection rate of the technique was 76.6%. We found a sensitivity of 100%, a specificity of 75,5%, a negative predictive value of 100% and a false negative rate of 0%. We observed a lymphovascular and neurological morbidity in 6.4% (3/47), and 8.5% (4/47) respectively. Conclusion The SLNB would allow a decrease in the morbidity associated with PL. It seems to be a trend towards a more conservative and less aggressive surgery. Accurate selection of patients is key point. Disclosure Nothing to disclose.